These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 37109734)

  • 21. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An updated review of lipid-modifying therapy.
    Simons LA
    Med J Aust; 2019 Jul; 211(2):87-92. PubMed ID: 31006138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A decade of progress in the management of dyslipidemia].
    Wallemacq C; Paquot N
    Rev Med Liege; 2020 May; 75(5-6):386-391. PubMed ID: 32496685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Status of Dyslipidemia Treatment for Stroke Prevention.
    Aradine E; Hou Y; Cronin CA; Chaturvedi S
    Curr Neurol Neurosci Rep; 2020 Jun; 20(8):31. PubMed ID: 32572590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status of lipid management in acute coronary syndrome.
    Fujisue K; Tsujita K
    J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
    Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
    Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.
    Nguy J; Hitchen SA; Lan NSR; Dwivedi G; Larbalestier R; Yeap BB; Fegan PG
    Intern Med J; 2023 Jun; 53(6):994-1001. PubMed ID: 35112773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience).
    Oren O; Kludtke EL; Kopecky SL
    Am J Cardiol; 2019 Dec; 124(11):1669-1673. PubMed ID: 31740018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
    Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
    Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease.
    Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS
    J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying Patients for Nonstatin Therapy.
    Robinson JG; Watson KE
    Rev Cardiovasc Med; 2018; 19(S1):S1-S8. PubMed ID: 30207552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances.
    Atar D; Langslet G; Tonstad S
    Kardiol Pol; 2022; 80(7-8):741-749. PubMed ID: 35521719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
    Gunta SP; O'Keefe JH; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2023; 79():12-18. PubMed ID: 36871887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
    Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
    Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.